The ADC targets HER3, is internalized, and releases deruxtecan (DXd) that inhibits topoisomerase I to cause DNA damage and apoptosis. Killing is driven by HER3 binding; topoisomerase I is the intracellular payload target, not the antigen used for directing cytotoxicity.